Complex Endometriosis Center

At the heart of scientific advances

"In 2019 and 2020, the CEC was the first center to be able to offer a GnRH antagonist, linzagolix, in clinical trials published in 2021 and 2022. This molecule has significantly reduced adenomyosis symptoms and uterine volume. We are proud today to present our post-treatment experience in order to consider further clinical trials."

Go Back